| Drug General Information |
| Drug ID |
D04PJO
|
| Former ID |
DNC007582
|
| Drug Name |
2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H14N4
|
| Canonical SMILES |
CC1=CC(=CC=C1)N2C=C3C4=CC=CC=C4N=C(C3=N2)N
|
| InChI |
1S/C17H14N4/c1-11-5-4-6-12(9-11)21-10-14-13-7-2-3-8-15(13)19-17(18)16(14)20-21/h2-10H,1H3,(H2,18,19)
|
| InChIKey |
NJFGXLMDWIXVEW-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Adenosine A1 receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Adenosine A2a receptor |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Morphine addictionhsa04015:Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Parkinson's disease
|
|
Alcoholism
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Reactome
|
Adenosine P1 receptors
|
|
G alpha (i) signalling eventsR-HSA-187024:NGF-independant TRKA activation
|
|
G alpha (s) signalling events
|
|
Surfactant metabolism
|
|
WikiPathways
|
Nucleotide GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP80:Nucleotide GPCRs
|
|
Monoamine Transport
|
|
NGF signalling via TRKA from the plasma membrane
|
|
GPCR downstream signaling
|
|
GPCRs, Other
|
| References |
| REF 1 | J Med Chem. 2007 Aug 23;50(17):4061-74. Epub 2007 Aug 1.New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. |
|---|
